DK1163256T3 - Hemihydrat af 16.alfa.-bromepiandrosteron - Google Patents

Hemihydrat af 16.alfa.-bromepiandrosteron

Info

Publication number
DK1163256T3
DK1163256T3 DK00918365T DK00918365T DK1163256T3 DK 1163256 T3 DK1163256 T3 DK 1163256T3 DK 00918365 T DK00918365 T DK 00918365T DK 00918365 T DK00918365 T DK 00918365T DK 1163256 T3 DK1163256 T3 DK 1163256T3
Authority
DK
Denmark
Prior art keywords
bromoepiandrosterone
hemihydrate
alpha
Prior art date
Application number
DK00918365T
Other languages
Danish (da)
English (en)
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Carvalho Dos Anjos Luis Dan De
William Heggie
Patrick T Prendergast
Christopher L Reading
Krupakar Paul Thadikonda
Russell Neil Vernon
Original Assignee
Hollis Eden Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals filed Critical Hollis Eden Pharmaceuticals
Application granted granted Critical
Publication of DK1163256T3 publication Critical patent/DK1163256T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00918365T 1999-03-23 2000-03-23 Hemihydrat af 16.alfa.-bromepiandrosteron DK1163256T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12605699P 1999-03-23 1999-03-23
US14002899P 1999-06-16 1999-06-16
US41490599A 1999-10-08 1999-10-08
US16404899P 1999-11-08 1999-11-08

Publications (1)

Publication Number Publication Date
DK1163256T3 true DK1163256T3 (da) 2004-06-28

Family

ID=27494614

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00918365T DK1163256T3 (da) 1999-03-23 2000-03-23 Hemihydrat af 16.alfa.-bromepiandrosteron

Country Status (22)

Country Link
EP (1) EP1163256B1 (enExample)
JP (1) JP2002540119A (enExample)
KR (2) KR20070007394A (enExample)
CN (1) CN1243767C (enExample)
AP (1) AP2001002285A0 (enExample)
AT (1) ATE259825T1 (enExample)
AU (1) AU781997B2 (enExample)
BR (1) BR0009476A (enExample)
CA (1) CA2365081A1 (enExample)
CZ (1) CZ20013420A3 (enExample)
DE (1) DE60008353T2 (enExample)
DK (1) DK1163256T3 (enExample)
ES (1) ES2215631T3 (enExample)
HK (1) HK1046002B (enExample)
HU (1) HUP0203429A3 (enExample)
IL (1) IL144916A0 (enExample)
NO (2) NO320801B1 (enExample)
NZ (1) NZ513803A (enExample)
OA (1) OA11850A (enExample)
PT (1) PT1163256E (enExample)
RU (2) RU2417792C2 (enExample)
WO (1) WO2000056757A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
EP1832598A3 (en) 1999-09-30 2008-01-02 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatment of androgen receptor driven conditions
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
EP2135611A1 (en) 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
FR2829697B1 (fr) * 2001-09-14 2004-03-19 Mayoly Spindler Lab Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin
US20040138187A1 (en) 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
KR101293350B1 (ko) * 2003-12-26 2013-08-05 다이쇼 세이야꾸 가부시끼가이샤 호중구증다 억제제
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
CN106565654B (zh) * 2016-10-14 2018-08-31 云南中烟工业有限责任公司 一种从白云参中提取的新型黄酮类化合物、其制备方法及其用途
US20210038554A1 (en) * 2018-06-01 2021-02-11 Societe Des Produits Nestle S.A. Dietary butyrate
US10836788B2 (en) 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof
JP2023504349A (ja) * 2019-12-05 2023-02-03 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 食品用ブチレート
CN114907333B (zh) * 2022-05-11 2023-07-04 中国人民解放军军事科学院军事医学研究院 环丙甲酰胺衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH197784A (de) * 1934-05-25 1938-05-15 Schering Kahlbaum Ag Verfahren zu Darstellung von D5,6-trans-Androstendiol-3,17.
IL72566A (en) * 1983-08-02 1988-08-31 Research Corp Androst-5-en-17-one and 5alpha-androstan-17-one derivatives and pharmaceutical compositions containing the same
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
JPH0289327A (ja) * 1988-09-27 1990-03-29 Matsushita Electron Corp 銀ペースト塗布装置
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates

Also Published As

Publication number Publication date
NO20014588L (no) 2001-11-21
KR100717897B1 (ko) 2007-05-14
HK1046002B (zh) 2006-10-20
BR0009476A (pt) 2002-02-19
RU2295534C2 (ru) 2007-03-20
CZ20013420A3 (cs) 2002-04-17
KR20020003217A (ko) 2002-01-10
EP1163256A1 (en) 2001-12-19
NO320801B1 (no) 2006-01-30
NO20014588D0 (no) 2001-09-21
NZ513803A (en) 2004-06-25
AU781997B2 (en) 2005-06-23
DE60008353D1 (de) 2004-03-25
CN1355809A (zh) 2002-06-26
JP2002540119A (ja) 2002-11-26
AP2001002285A0 (en) 2001-12-31
AU3919000A (en) 2000-10-09
HUP0203429A3 (en) 2004-07-28
ES2215631T3 (es) 2004-10-16
HK1046002A1 (en) 2002-12-20
CA2365081A1 (en) 2000-09-28
NO20056167L (no) 2001-11-21
ATE259825T1 (de) 2004-03-15
DE60008353T2 (de) 2005-09-08
WO2000056757A1 (en) 2000-09-28
EP1163256B1 (en) 2004-02-18
HUP0203429A2 (hu) 2003-01-28
IL144916A0 (en) 2002-06-30
OA11850A (en) 2006-03-06
RU2001128881A (ru) 2003-09-27
RU2417792C2 (ru) 2011-05-10
PT1163256E (pt) 2004-07-30
RU2006133273A (ru) 2008-03-27
KR20070007394A (ko) 2007-01-15
CN1243767C (zh) 2006-03-01

Similar Documents

Publication Publication Date Title
DE69932650D1 (de) Zementierkopf
IS6120A (is) Lyfjablanda
DK1163256T3 (da) Hemihydrat af 16.alfa.-bromepiandrosteron
DE69931821D1 (de) Wärmehärtbare pulverlack-zusammensetzung
DE60016836D1 (de) Resistzusammensetzung
DE69943245D1 (de) Gaserzeugende zusammensetzung
DE59901977D1 (de) Analog-digital-umsetzer
NO20013013D0 (no) <alfa>v<beta>6-integrininhibitorer
EP1225377A4 (en) SEAL RING
DE69803856D1 (de) Flash Analog-Digitalwandler
DE69804218D1 (de) Zementzusammensetzung
NO990937L (no) Kunstig rev
FR2791258B1 (fr) Composition amincissante
FI19992609L (fi) Uusi koostumus
DE60020682D1 (de) Resorcinenthaltende zusammensetzung
ID27329A (id) Komposisi penghambat
DE60021345D1 (de) Chromenverbindungen
NO20030419D0 (no) 16<alfa>-metyl- eller etyl-substituerte estrogener
ATE301689T1 (de) Auskleidungszusammensetzung
DE50000810D1 (de) Stabilisierte Monomerzusammensetzung
NO20010280D0 (no) <Alfa>-aminosyrefenylesterderivater
DE60008950D1 (de) Keramikzusammensetzung
DE50012335D1 (de) Brennofen
FR2792306B1 (fr) Composition derivee de bi26mo10o69
DK1141012T3 (da) Modifikation af Interferon Alfa Fremstilling